U.S. In Vitro Diagnostics (IVD) Market Outlook $78.9B

Market Outlook

By 2035, the U.S. In Vitro Diagnostics (IVD) Market is expected to reach approximately USD 78.90 billion, expanding at a CAGR of 6.05% during the forecast period 2026–2035. The market is estimated at USD 43.85 billion in 2025, with historical analysis covering 2021 to 2024. Values in this report are expressed in USD billions.

The U.S. in vitro diagnostics industry represents one of the most recurring and strategically important revenue pools wiing, diagnosis, treatment selection, therapeutic monitoring, hospital admission, emergency medicine, preventive care, oncology, infectious disease management, chronic disease surveillance, and population health. Unlike many medical device markets that depend primarily on episodic capital replacement or procedural volumes, IVD combines instrument placements with high-frequency reagent, assay, consumable, software, and laboratory service revenue.

The size of the underlying testing infrastructure gives the United States unusual market depth. Approximately 320,000 laboratory entities operate under the Clinical Laboratory Improvement Amendments framework, spanning hospital laboratories, independent reference laboratories, physician-office laboratories, ambulatory settings, public-health laboratories, pharmacies, clinics, and other testing locations. This installed infrastructure creates a large addressable base for chemistry analyzers, immunoassay systems, hematology instruments, molecular platforms, microbiology systems, coagulation analyzers, pathology technologies, reagents, quality controls, and point-of-care diagnostics.

Demand is reinforced by the scale of chronic and infectious disease. Approximately 38.4 million U.S. adults have diabetes, while an estimated 35.5 million adults live with chronic kidney disease. More than 2.04 million new cancer cases were expected in the United States in 2025, supporting continuing expansion of tissue diagnostics, immunohistochemistry, companion diagnostics, molecular profiling, liquid biopsy, minimal residual disease testing, and advanced genomic assays. Infectious disease testing also remains structurally important. During the 2024–2025 influenza season, clinical laboratories participating in national surveillance tested nearly 4.0 million respiratory specimens for influenza, demonstrating the testing volumes that can be generated by a single respiratory disease category.

The historical market expanded from an estimated USD 36.10 billion in 2021 to USD 41.42 billion in 2024. Growth during this period reflected normalization of routine laboratory testing after pandemic disruptions, continued utilization of molecular diagnostics, expansion of oncology biomarkers, greater adoption of high-throughput automation, and rising demand for decentralized diagnostics. The market reached an estimated USD 43.85 billion in 2025, supported by recurring reagent consumption, laboratory consolidation, increasing diagnostic complexity, expansion of precision medicine, and continued replacement of aging diagnostic platforms.

From 2026 through 2035, value creation will increasingly shift toward assays that influence clinical decisions rather than simply produce analytical results. Molecular oncology, companion diagnostics, syndromic infectious disease panels, antimicrobial resistance testing, high-sensitivity cardiac biomarkers, automated immunoassays, digital pathology, mass spectrometry, genomic diagnostics, and connected point-of-care testing will capture a growing proportion of industry economics.

Introduction

According to the U.S. In Vitro Diagnostics Market Report, the industry is shaped by a combination of exceptionally high testing volumes, sophisticated clinical laboratories, strong reimbursement infrastructure, large chronic disease populations, advanced hospital networks, extensive physician-office testing, and one of the world’s most commercially important precision medicine ecosystems.

In vitro diagnostics examine specimens such as blood, serum, plasma, urine, tissue, cerebrospinal fluid, respiratory samples, stool, saliva, and other biological materials outside the human body. The resulting information may be used for disease detection, risk assessment, treatment selection, drug monitoring, disease progression measurement, infection control, preventive screening, and confirmation of therapeutic response.

The U.S. IVD market is therefore considerably broader than laboratory instrumentation. Revenue is generated through reagents and consumables, analyzers, molecular cartridges, test kits, controls, calibrators, software, middleware, interpretation tools, maintenance contracts, pathology products, genomic assays, reference testing, and specialized diagnostic services. These recurring consumables model makes IVD economically attractive because a single instrument placement can create reagent demand over several years.

The market is also closely linked to laboratory workflow economics. U.S. health systems are under continuing pressure to manage labor shortages, improve turnaround time, consolidate testing, reduce manual sample handling, standardize platforms across multiple hospitals, and minimize laboratory errors. Consequently, purchasing decisions increasingly consider cost per reportable result, analyzer uptime, automation potential, reagent utilization, staffing requirements, middleware compatibility, specimen throughput, quality-control burden, and the ability to connect laboratory data with electronic medical records.

The U.S. population exceeded 341 million in 2025, with people aged 65 years and older representing a substantial and growing share of the population. An aging population increases demand for metabolic testing, cardiac biomarkers, renal monitoring, coagulation testing, cancer diagnostics, infectious disease assays, endocrinology, hematology, and therapeutic monitoring. Testing intensity typically rises as patients accumulate chronic conditions, making demographic aging a durable IVD growth driver.

At the same time, the industry is moving away from a simple centralized-laboratory model. High-volume core laboratories remain essential, but diagnostic capacity is increasingly distributed across emergency departments, urgent-care centers, physician offices, oncology practices, pharmacies, ambulatory facilities, retail health settings, and homes. The winning business models will therefore be those capable of serving both highly automated central laboratories and decentralized testing environments without sacrificing analytical quality or connectivity.

Key Market Drivers: What’s Fueling the U.S. In Vitro Diagnostics Market Boom?

The first major driver is the scale of chronic disease requiring recurring laboratory monitoring. Diabetes alone affects approximately 38.4 million U.S. adults and creates continuous testing demand for glucose, HbA1c, renal function, lipid profiles, liver function, urine albumin, and related metabolic markers. Chronic kidney disease affects approximately 35.5 million adults and requires frequent chemistry, hematology, electrolyte, and renal biomarker testing. These are not one-time diagnostic events; they generate repeat testing throughout the patient journey.

A second driver is the expanding role of diagnostics in oncology. More than 2 million new U.S. cancer cases annually create a substantial clinical need for histopathology, immunohistochemistry, fluorescence in situ hybridization, PCR, next-generation sequencing, circulating tumor DNA analysis, molecular residual disease assessment, companion diagnostics, and recurrence monitoring. Oncology is particularly attractive because diagnostic value is increasingly tied to therapeutic selection. When a biomarker determines whether a patient is eligible for a targeted drug, the clinical and economic value of the test rises considerably.

A third driver is persistent infectious disease testing. The post-pandemic market is no longer defined by extraordinary COVID-19 testing volumes, but respiratory infections, sexually transmitted infections, hepatitis, HIV, gastrointestinal infections, hospital-acquired infections, sepsis, bloodstream infections, and antimicrobial resistance continue to generate large testing requirements. At least 1.7 million U.S. adults develop sepsis annually, while antimicrobial-resistant infections remain a significant hospital and public-health challenge. These conditions increase demand for blood culture, molecular identification, susceptibility testing, syndromic panels, procalcitonin, lactate, and rapid pathogen detection.

A fourth driver is laboratory automation and staffing economics. U.S. laboratories face pressure to process more samples with constrained technical labor. Integrated analyzers, track systems, automated specimen processing, digital morphology, intelligent quality control, remote diagnostics, middleware, and algorithm-supported result review can reduce manual intervention. Large health systems increasingly prefer standardized laboratory architectures that allow common reagents, shared service contracts, centralized inventory, and harmonized clinical results across multiple sites.

A fifth driver is the expansion of point-of-care and decentralized testing. Hospitals are increasingly moving selected diagnostics closer to the patient when faster turnaround time can influence treatment. Blood gas testing, cardiac biomarkers, glucose, coagulation, respiratory pathogens, pregnancy, infectious disease screening, urinalysis, and selected molecular assays can be performed outside centralized laboratories. Faster testing can reduce emergency-department decision time, support antimicrobial stewardship, accelerate isolation decisions, and shorten time to treatment.

A sixth driver is precision medicine and companion diagnostics. Pharmaceutical development is becoming increasingly biomarker driven, particularly in oncology. Diagnostic manufacturers that participate early in therapeutic development can build commercially valuable relationships around companion assays, regulatory submissions, clinical trial testing, and installed instrument platforms. Companion diagnostics can also protect reagent demand because therapeutic prescribing depends upon validated testing methods.

A seventh driver is the scale of Medicare and commercial reimbursement for laboratory testing. The U.S. reimbursement environment is complex and can exert pricing pressure, but it also provides established payment pathways across thousands of laboratory procedures. Commercial success increasingly depends on demonstrating clinical utility, medical necessity, coding clarity, payer coverage, and health-economic value rather than analytical performance alone.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. IVD market is increasingly centered on producing more clinically actionable information from smaller samples, with faster turnaround and less laboratory labor. The competitive question is no longer simply whether an analyzer can measure an analyte accurately. Manufacturers are being evaluated on how effectively their platforms improve clinical workflow and reduce total diagnostic cost.

Molecular diagnostics remain one of the industry’s strongest innovation engines. Multiplex PCR systems can identify multiple pathogens from a single specimen, while cartridge-based platforms have reduced the technical complexity associated with molecular testing. Molecular platforms are increasingly being designed for lower-complexity settings, enabling near-patient testing for respiratory pathogens, sexually transmitted infections, gastrointestinal pathogens, and other conditions.

Next-generation sequencing is creating another structural growth opportunity. Oncology laboratories increasingly require broad genomic profiling to identify actionable mutations, genomic signatures, microsatellite instability, tumor mutational burden, homologous recombination deficiencies, and other clinically relevant biomarkers. As targeted and biomarker-selected therapies increase, comprehensive genomic profiling can replace sequential single-gene testing in selected clinical scenarios.

Liquid biopsy is moving from an emerging technology toward a clinically relevant diagnostic category. Plasma-based testing can detect tumor-derived genetic material without requiring a tissue biopsy in certain use cases. The most commercially important opportunities include therapy selection, recurrence monitoring, treatment response, and molecular residual disease. Clinical adoption will remain evidence dependent, but the value proposition is strong when testing can identify relapse earlier or provide molecular information when tissue is unavailable.

Immunoassay platforms are also undergoing significant improvement. High-sensitivity cardiac troponin, infectious disease serology, endocrine testing, reproductive health, therapeutic drug monitoring, autoimmune markers, and oncology biomarkers remain major sources of laboratory volume. Manufacturers are competing through faster processing, broader assay menus, improved sensitivity, compact system footprints, automation, and integrated chemistry-immunoassay workflows.

Microbiology is becoming more automated and data intensive. Traditional culture remains important, but automated identification, antimicrobial susceptibility testing, MALDI-TOF mass spectrometry, multiplex molecular panels, and rapid resistance-marker testing are reducing time to actionable results. This is particularly important in sepsis, where hours can influence antimicrobial selection and patient outcomes.

Artificial intelligence and digital diagnostics are emerging across pathology, hematology, microbiology, laboratory quality management, and workflow prioritization. Digital image analysis can assist pathologists with cell detection, biomarker quantification, slide review, and case prioritization. AI-supported laboratory systems can also identify unusual result patterns, automate selected quality checks, and reduce repetitive manual work.

The strongest manufacturers will increasingly compete through complete laboratory ecosystems combining instruments, assays, automation, informatics, connectivity, service, and clinical evidence rather than through individual test kits.

Segmentation Insights

The U.S. In Vitro Diagnostics Market is segmented on the basis of product and service, technology, application, end user, and region.

By Product and Service

Reagents and consumables represent the largest and most economically important product category. The segment includes assay reagents, cartridges, test kits, calibrators, controls, stains, probes, antibodies, extraction materials, sequencing consumables, and sample-preparation products. Recurring reagent consumption makes this segment central to IVD business models. Instrument placements are frequently structured to support long-term reagent pull-through, making assay menu breadth and customer retention important competitive advantages.
Instruments and analyzers include clinical chemistry systems, immunoassay analyzers, molecular platforms, hematology analyzers, coagulation systems, microbiology instruments, pathology equipment, blood gas analyzers, urinalysis systems, sequencing platforms, and point-of-care devices. Large health systems increasingly favor scalable instrument families that can serve core laboratories and satellite facilities using common reagent and informatics architectures.
Software and laboratory informatics are becoming strategically important as laboratories manage higher sample volumes and more complex results. Middleware, laboratory information connectivity, autoverification, quality-control software, remote instrument monitoring, image analysis, molecular interpretation, and data-management platforms can reduce operational friction. Informatics is also becoming an important source of customer retention because switching laboratory ecosystems can involve substantial validation and workflow disruption.
Diagnostic and specialty testing services include high-complexity molecular testing, genomic profiling, hereditary disease testing, advanced oncology assays, esoteric laboratory services, and specialized reference testing. Service-based diagnostics are particularly relevant where test complexity, sample volume, or regulatory requirements make decentralized deployment of an instrument uneconomic.

By Technology

Immunoassay and immunochemistry represent a major technology segment because of their broad application across endocrine disease, infectious disease, reproductive health, cardiology, oncology, autoimmune disease, and therapeutic monitoring. Laboratory consolidation supports demand for high-throughput immunoassay systems, while smaller hospitals and clinics require compact analyzers capable of supporting essential assay menus.
Clinical chemistry remains one of the highest-volume IVD technologies. Metabolic panels, renal markers, liver enzymes, electrolytes, glucose, lipids, enzymes, proteins, and other routine chemistry tests are fundamental to inpatient, outpatient, emergency, and chronic disease management. Although the segment is mature, its recurring testing volumes provide dependable reagent revenue.
Molecular diagnostics are expected to record above-market growth through 2035. PCR, real-time PCR, digital PCR, nucleic acid amplification, hybridization, and sequencing technologies support infectious disease detection, oncology, genetic testing, women’s health, transplantation, pharmacogenomics, and inherited disease. Growth will be particularly strong where molecular results directly influence therapy.
Hematology and coagulation diagnostics are essential to hospital and reference laboratory workflows. Complete blood counts, cellular morphology, coagulation studies, platelet testing, hemostasis, thrombosis assessment, and blood-related disease diagnostics generate substantial routine testing volumes. Digital morphology and automated cell classification are expected to reduce manual review burden.
Microbiology and other advanced diagnostic technologies include culture systems, antimicrobial susceptibility testing, mass spectrometry, urinalysis, histology, cytology, immunohistochemistry, flow cytometry, and emerging digital diagnostic approaches. Microbiology will benefit from antimicrobial stewardship, hospital infection-control requirements, and demand for faster organism identification.

By Application

Infectious disease diagnostics remain a major application area. Respiratory viruses, sexually transmitted infections, HIV, hepatitis, bloodstream infections, gastrointestinal pathogens, urinary infections, hospital-acquired infections, and antimicrobial resistance generate demand across centralized laboratories and point-of-care settings. The 2024–2025 influenza season alone resulted in tens of millions of illnesses and almost 4 million influenza specimens being tested through reporting clinical laboratories.
Oncology diagnostics represent one of the fastest-growing value segments. Tissue pathology, immunohistochemistry, molecular diagnostics, companion tests, liquid biopsy, genomic profiling, and molecular residual disease testing are increasingly integrated into cancer treatment pathways. More than 2.04 million new U.S. cancer cases in 2025 provide a large addressable patient pool for diagnostic stratification and longitudinal testing.
Diabetes and metabolic disease diagnostics provide high recurring test volumes. Glucose and HbA1c testing remain core categories, while diabetes-related renal, cardiovascular, lipid, and liver testing expands the broader laboratory opportunity. Large primary-care populations and longitudinal disease management make this a particularly stable segment.
Cardiology and critical care diagnostics include troponin, natriuretic peptides, coagulation markers, blood gas analysis, lactate, inflammatory markers, and other tests used in emergency and inpatient environments. Faster turnaround is economically valuable because results can influence admission, discharge, antimicrobial therapy, interventional decisions, and intensive-care management.
Renal, autoimmune, endocrine, women’s health, and other applications collectively represent a substantial market. Thyroid testing, reproductive hormones, pregnancy testing, autoimmune antibodies, kidney function, transplantation testing, fertility diagnostics, vitamin assessment, and therapeutic drug monitoring create diversified recurring demand across laboratories.

By End User

Hospitals and health systems represent the largest end-user segment. They operate central laboratories, emergency testing, intensive-care diagnostics, blood banks, pathology departments, microbiology laboratories, molecular laboratories, and point-of-care networks. Large systems increasingly negotiate enterprise agreements covering instruments, reagents, automation, service, and informatics across multiple facilities.
Independent and reference laboratories are critical to U.S. testing infrastructure. Large reference laboratories process substantial national volumes, while regional and specialty laboratories provide esoteric, molecular, pathology, genetic, and oncology testing. Scale allows these organizations to operate highly automated workflows and negotiate aggressively on reagent economics.
Physician offices, clinics, urgent-care centers, and ambulatory facilities are becoming more important as testing moves closer to the patient. Ease of use, CLIA-waived status where applicable, small instrument footprints, rapid turnaround, and simple connectivity are important purchasing criteria.
Academic, specialty, oncology, and research laboratories are important early adopters of advanced molecular, genomic, pathology, and biomarker technologies. These institutions frequently participate in clinical trials, assay validation, translational research, and precision medicine programs.
Home and consumer testing environments represent a smaller but strategically important segment. Pregnancy tests, glucose monitoring, infectious disease testing, specimen collection, and selected wellness diagnostics have established consumer acceptance. Future adoption will depend on accuracy, regulatory clearance, clinician integration, reimbursement, and the ability to convert consumer results into appropriate clinical action.

Regional Insights: Where the Market is Growing Fastest

The South is the largest U.S. IVD regional market, while the West is expected to record the fastest growth through 2035. The Northeast remains one of the highest-value markets for specialized oncology, genomic, and academic laboratory testing, while the Midwest provides a large, stable base of hospital and reference laboratory demand.

South

The South is estimated at approximately USD 16.66 billion in 2025 and is expected to approach USD 30.20 billion by 2035. The region includes Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, the District of Columbia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas.

Texas and Florida are the region’s largest state-level opportunities. Texas had an estimated population of more than 31.7 million in 2025, making it the second-largest state in the country. Houston, Dallas-Fort Worth, Austin, and San Antonio support extensive hospital networks, cancer programs, academic medical centers, reference laboratories, and rapidly growing outpatient care infrastructure. High diabetes burden and population growth support routine chemistry, immunoassay, hematology, molecular, and point-of-care testing.

Florida exceeded 23.4 million residents in 2025 and has one of the country’s largest older-adult populations. This creates strong demand for oncology testing, cardiac biomarkers, metabolic panels, renal diagnostics, coagulation, infectious disease testing, and hospital laboratory services. The state’s large Medicare population makes reimbursement strategy particularly important.

North Carolina, Georgia, Tennessee, Virginia, and Maryland are strategically important because of growing populations, large hospital systems, biotechnology activity, academic medical centers, and specialty laboratory capacity. North Carolina’s Research Triangle strengthens the state’s molecular diagnostics and life-sciences ecosystem. Georgia benefits from Atlanta’s role as a major healthcare and public-health hub, while Tennessee contains nationally significant hospital, laboratory, and healthcare services organizations.

Alabama, Mississippi, Louisiana, Kentucky, West Virginia, Arkansas, and Oklahoma present a different opportunity profile. These states have substantial chronic disease burden but more uneven access to specialist laboratories and advanced diagnostic infrastructure. Platforms that improve access through regional laboratory networks, point-of-care diagnostics, simplified molecular testing, and high-reliability automation can therefore create meaningful value.

The South is expected to remain the largest regional market because it combines rapid population growth, high chronic disease prevalence, expanding hospital capacity, large Medicare populations, and strong demand for decentralized testing.

West

The West is estimated at approximately USD 10.03 billion in 2025 and is projected to reach about USD 19.20 billion by 2035, representing the fastest regional expansion. The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is the most important state market in the West and the largest state by population, with approximately 39.4 million residents in 2025. Its importance extends well beyond population. California contains major academic medical centers, integrated health systems, biotechnology companies, sequencing firms, diagnostics developers, oncology centers, and venture-funded precision medicine companies.

The state is particularly influential in next-generation sequencing, liquid biopsy, companion diagnostics, digital pathology, laboratory automation, and data-intensive diagnostics. Technologies adopted at major California institutions can influence broader commercial adoption because these providers frequently participate in clinical studies, guideline development, and precision medicine programs.

Washington and Oregon have sophisticated integrated health systems and strong adoption of digitally connected care. Seattle’s biotechnology environment also supports advanced molecular testing and translational diagnostics.

Arizona and Nevada are attractive growth markets because of population expansion and migration of older adults. Arizona exceeded 7.6 million residents in 2025 and supports large healthcare networks in Phoenix and Tucson. As these populations age, demand will increase for chemistry, immunoassay, oncology, cardiac, renal, and infectious disease diagnostics.

Colorado and Utah combine strong demographic growth with research-intensive provider systems and technology adoption. Utah is particularly relevant to genetic and hereditary disease testing because of its established genomics ecosystem. New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii are smaller in absolute market value but create opportunities for decentralized platforms capable of delivering reliable testing where centralized laboratory access may be limited.

The West should gain national market share through 2035 as IVD revenue becomes increasingly linked to genomics, precision oncology, digital pathology, biotechnology research, and decentralized diagnostics.

Northeast

The Northeast represented an estimated USD 9.64 billion in 2025 and is forecast to reach approximately USD 16.80 billion by 2035. The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Maine, Vermont, New Hampshire, and Rhode Island.

New York is the largest Northeast market, supported by a population of roughly 20 million, high hospital density, major academic medical centers, oncology institutions, and extensive independent laboratory testing. New York City generates significant demand across hospital laboratories, molecular oncology, infectious disease testing, pathology, women’s health, reproductive diagnostics, and specialty laboratory services.

Pennsylvania is another major diagnostic market, with more than 13 million residents and large medical centers in Philadelphia and Pittsburgh. The state supports substantial hospital laboratory volumes and strong adoption of oncology, molecular, and pathology diagnostics.

Massachusetts carries disproportionate strategic importance relative to its population because of Boston’s biotechnology, pharmaceutical, hospital, genomic, and academic research ecosystem. Diagnostic companies frequently interact with Massachusetts-based biopharma firms during biomarker development and clinical trials, making the state an important market for companion diagnostics and translational testing.

New Jersey combines major pharmaceutical industry presence with a dense healthcare market, supporting clinical trials, biomarker programs, oncology testing, hospital diagnostics, and commercial laboratory operations. Connecticut, Rhode Island, New Hampshire, Maine, and Vermont are smaller markets but benefit from high insurance coverage, established health systems, and relatively mature diagnostic utilization.

The Northeast is expected to remain one of the highest-value regions per test because it has a larger concentration of complex oncology, genomic, transplant, academic, and specialty testing. Procurement is often evidence intensive, making clinical validation, reimbursement evidence, and laboratory workflow integration particularly important.

Midwest

The Midwest accounted for an estimated USD 7.52 billion in 2025 and is expected to reach approximately USD 12.70 billion by 2035. The region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Minnesota, Iowa, Missouri, Kansas, Nebraska, North Dakota, and South Dakota.

Illinois, Ohio, Michigan, and Minnesota represent the largest opportunities. Illinois benefits from Chicago’s extensive healthcare infrastructure, academic hospitals, pathology laboratories, and reference testing capacity. Ohio has major integrated health systems and nationally recognized medical institutions that support advanced laboratory medicine, oncology diagnostics, and molecular testing.

Michigan provides significant hospital laboratory demand linked to a population exceeding 10 million and a substantial chronic disease burden. Minnesota is strategically relevant because of its broader medical technology ecosystem and sophisticated healthcare delivery infrastructure.

Wisconsin, Indiana, Missouri, Iowa, and Kansas represent dependable markets for routine chemistry, immunoassay, hematology, microbiology, and hospital diagnostics. Laboratory consolidation and regional health-system purchasing can produce large multi-site opportunities for manufacturers capable of providing standardized platforms.

Nebraska, North Dakota, and South Dakota have smaller populations and greater geographic dispersion. These states increase the economic value of point-of-care testing, compact molecular diagnostics, remote instrument support, and strong regional reference laboratory logistics.

The Midwest is expected to grow more moderately than the South or West but will remain an important base of recurring reagent revenue because of its large hospital networks, chronic disease burden, and established laboratory infrastructure.

Key Market Players

The U.S. In Vitro Diagnostics Competitive Landscape is moderately consolidated across high-volume core laboratory platforms but considerably more fragmented in molecular oncology, genomics, specialty testing, and decentralized diagnostics.

Large diversified manufacturers compete through installed analyzer bases, reagent menus, service networks, automation platforms, molecular portfolios, and enterprise laboratory contracts. Emerging competitors increasingly enter through narrow but high-value clinical use cases such as liquid biopsy, molecular residual disease, genomic profiling, rapid syndromic diagnostics, and AI-enabled pathology.

Some of the key players in the U.S. In Vitro Diagnostics industry are:

Roche Diagnostics
Abbott Laboratories
Siemens Healthineers
Danaher Corporation
Beckman Coulter Diagnostics
Cepheid
Thermo Fisher Scientific
Becton, Dickinson and Company
bioMérieux
QuidelOrtho Corporation
Hologic
Sysmex Corporation
Bio-Rad Laboratories
QIAGEN
Agilent Technologies
Illumina
DiaSorin
Werfen
Revvity
Fujirebio
SEKISUI Diagnostics
Exact Sciences
Guardant Health
Natera
Caris Life Sciences

Roche, Abbott, Siemens Healthineers, Danaher, Beckman Coulter, Thermo Fisher Scientific, BD, bioMérieux, Sysmex, and QuidelOrtho have broad positions across traditional IVD categories or laboratory platforms. Their competitive strength comes from installed instrument bases, large assay menus, service infrastructure, regulatory capabilities, and long-term hospital relationships.

Cepheid, Hologic, QIAGEN, and DiaSorin are influential in molecular and infectious disease testing. Illumina, Thermo Fisher Scientific, Agilent, and other genomics-focused companies enable sequencing and molecular workflows that underpin precision medicine.

Exact Sciences, Guardant Health, Natera, and Caris Life Sciences illustrate the expansion of the competitive landscape beyond traditional analyzer companies. Their businesses are centered on high-value oncology testing, genomic information, recurrence monitoring, screening, and treatment selection.

Future market share will increasingly depend on the ability to prove clinical utility and workflow economics. Manufacturers that reduce laboratory labor, improve turnaround time, consolidate multiple tests onto one platform, increase reagent predictability, provide reliable service, and integrate results into clinical workflows will have significant advantages during health-system procurement.

Recent Developments

Recent developments in the U.S. IVD market demonstrate that precision oncology is becoming one of the most important sources of premium market growth. FDA-authorized companion diagnostics increasingly assess complex biomarkers rather than single analytes. Recent authorizations have included assays supporting targeted treatment decisions for breast, lung, prostate, gastrointestinal, ovarian, bladder, and other cancers.

Circulating tumor DNA and molecular residual disease are moving closer to mainstream clinical decision-making. In 2026, an FDA-authorized circulating tumor DNA-based companion diagnostic for muscle-invasive bladder cancer represented an important milestone for residual disease-guided oncology. Such developments support a broader commercial opportunity for blood-based cancer testing beyond initial tumor genotyping.

Comprehensive genomic profiling continues to expand as new targeted therapies reach the U.S. market. Tissue and plasma-based assays are increasingly being linked to drug labels, creating direct interdependence between pharmaceutical innovation and diagnostic utilization. This benefits IVD companies capable of participating in drug-development programs and navigating companion diagnostic regulation.

The regulatory environment for laboratory-developed tests has also changed materially. A federal district court vacated the FDA’s 2024 laboratory-developed test final rule in March 2025, and the FDA subsequently reverted the relevant regulatory text later in 2025. This reduced immediate regulatory disruption for many clinical laboratories, although oversight, quality expectations, clinical validation, and the longer-term policy environment remain important strategic issues for laboratory businesses and test manufacturers.

Medicare laboratory reimbursement remains another major strategic variable. The Clinical Laboratory Fee Schedule contains more than two thousand test records, illustrating the breadth and complexity of reimbursed diagnostic services. Laboratories and manufacturers will continue to monitor rate changes, private-payor data reporting requirements, advanced diagnostic laboratory test policy, and potential reductions affecting established assays.

Point-of-care molecular diagnostics are also moving beyond the pandemic-driven development cycle. Manufacturers are developing compact systems that can perform nucleic acid testing with simplified workflows in near-patient environments. The long-term opportunity lies less in mass COVID-19 testing and more in multipathogen respiratory testing, sexually transmitted infection testing, gastrointestinal disease, antimicrobial stewardship, and other areas where faster answers improve clinical decisions.

Automation remains a major capital investment priority among high-volume U.S. laboratories. Health systems increasingly seek integrated chemistry, immunoassay, hematology, molecular, and specimen-management solutions capable of reducing labor requirements. This favors manufacturers that can combine analyzers with pre-analytics, automation tracks, middleware, informatics, remote service, and enterprise contracting.

Conclusion

The U.S. In Vitro Diagnostics Market Size & Share is positioned to expand from approximately USD 43.85 billion in 2025 to USD 78.90 billion by 2035, representing a 6.05% CAGR during 2026–2035.

The fundamental strength of the market comes from recurring laboratory demand rather than a single disease or technology cycle. Routine chemistry, hematology, immunoassay, coagulation, microbiology, and pathology generate the industry’s dependable revenue base, while molecular diagnostics, companion diagnostics, genomic profiling, liquid biopsy, digital pathology, rapid infectious disease testing, and decentralized diagnostics provide higher-growth opportunities.

The most attractive opportunities will emerge where testing directly changes treatment decisions. Oncology is therefore expected to remain one of the strongest premium-value segments. Companion diagnostics, molecular residual disease, comprehensive genomic profiling, and liquid biopsy can command strategic value because they determine therapeutic eligibility or influence longitudinal treatment decisions.

In infectious disease, the opportunity is shifting from pandemic-scale single-pathogen testing toward multiplex diagnostics, antimicrobial resistance, rapid sepsis workflows, hospital infection control, sexually transmitted infections, respiratory disease, and decentralized molecular testing. Manufacturers that shorten time to actionable results can generate measurable economic value for hospitals.

Hospital procurement behavior will increasingly reward operational efficiency. Laboratories are being asked to manage rising diagnostic complexity despite workforce constraints and reimbursement pressure. Consequently, purchasing decisions will increasingly prioritize analyzer consolidation, reagent efficiency, automation, uptime, service performance, connectivity, and cost per reportable result.

Regional opportunity will be led by the South because of population scale, chronic disease burden, health-system growth, and expanding older-adult populations. The West will record the strongest innovation-led growth because of its concentration of genomics, biotechnology, precision medicine, and digital diagnostic activity. The Northeast will remain particularly important for complex oncology and academic testing, while the Midwest will provide stable recurring laboratory demand.

At the state level, California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Michigan, New Jersey, Massachusetts, Washington, Arizona, Minnesota, and Tennessee are expected to represent particularly important commercial markets based on population, laboratory infrastructure, hospital density, specialist care, and diagnostic innovation.

For manufacturers, investors, laboratory operators, healthcare systems, and pharmaceutical companies evaluating this market, the central strategic question is not simply how many laboratory tests will be performed. The more consequential issue is which tests will command increasing clinical value, which platforms will reduce laboratory operating cost, which diagnostic results will become essential to therapeutic decisions, and which companies will control the workflow connecting specimen collection to actionable clinical information.

The companies best positioned through 2035 will be those capable of combining analytical performance with workflow efficiency, regulatory execution, broad assay menus, reimbursement evidence, clinical utility, connectivity, and durable recurring-reagent economics. In the U.S. IVD market, the competitive advantage is increasingly shifting from the ability to generate a laboratory result to the ability to make that result faster, more actionable, more scalable, and more economically valuable to the healthcare system.

TABLE OF CONTENT

1. U.S. In Vitro Diagnostics (IVD) Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. IVD Reagent and Assay Manufacturers
1.6.2. Diagnostic Instrument and Analyzer Manufacturers
1.6.3. Molecular and Genomic Diagnostics Companies
1.6.4. Hospital Systems and Integrated Delivery Networks
1.6.5. Independent and Reference Laboratories
1.6.6. Physician Office, Clinic and Point-of-Care Testing Providers
1.6.7. Group Purchasing Organizations, Distributors and Laboratory Suppliers
1.6.8. Payers, Regulators and Clinical Decision-Makers

What this section provides: This section defines the U.S. IVD market boundary, study scope, research methodology, assumptions, diagnostic ecosystem, and stakeholder structure so clients understand how market revenues, testing demand, and forecasts are developed and validated.

2. U.S. In Vitro Diagnostics (IVD) Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.8. Laboratory Testing Volume and Reagent Consumption Outlook
2.9. High-Growth Technology and Clinical Application Matrix

What this section provides: This section gives decision-makers a concise view of market size, historical performance, forecast direction, testing demand, reagent economics, competitive intensity, and the diagnostic technologies and applications expected to create the strongest opportunities through 2035.

3. U.S. In Vitro Diagnostics (IVD) Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Chronic Disease and Aging Population Burden
3.1.2. Increasing Volume of Routine and Specialized Laboratory Testing
3.1.3. Expansion of Molecular Diagnostics and Precision Medicine
3.1.4. Growing Oncology Biomarker and Companion Diagnostic Utilization
3.1.5. Persistent Infectious Disease Testing Requirements
3.1.6. Laboratory Automation and Workforce Optimization
3.1.7. Expansion of Point-of-Care and Decentralized Testing
3.2. Restraints and Their Impact Analysis
3.2.1. Reimbursement and Clinical Laboratory Fee Schedule Pressure
3.2.2. High Capital Cost of Advanced Diagnostic Platforms
3.2.3. Laboratory Workforce Shortages and Technical Skill Gaps
3.2.4. Complex Regulatory and Clinical Validation Requirements
3.2.5. Pricing Pressure in Mature Routine Testing Categories
3.3. Opportunities and Their Impact Analysis
3.3.1. Next-Generation Sequencing and Comprehensive Genomic Profiling
3.3.2. Liquid Biopsy and Molecular Residual Disease Testing
3.3.3. Companion Diagnostics and Biomarker-Guided Therapeutics
3.3.4. Multiplex and Syndromic Infectious Disease Testing
3.3.5. AI-Assisted Pathology and Laboratory Workflow Automation
3.3.6. Decentralized Molecular and Point-of-Care Diagnostics
3.3.7. Antimicrobial Resistance and Rapid Sepsis Diagnostics
3.4. Challenges and Their Impact Analysis
3.4.1. Laboratory Test Reimbursement Compression
3.4.2. Assay Menu Differentiation in Mature Testing Categories
3.4.3. Interoperability and Laboratory Information System Integration
3.4.4. Maintaining Quality Across Decentralized Testing Networks
3.4.5. Evidence Requirements for High-Value Molecular Tests
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Laboratory Workflow Economics Analysis
3.7. Reagent Pull-Through and Installed-Base Economics Analysis
3.8. Laboratory Automation and Staffing Productivity Analysis
3.9. Health System and Reference Laboratory Procurement Behavior Analysis

What this section provides: This section explains the clinical, technological, economic, regulatory, reimbursement, and laboratory-operational forces affecting U.S. IVD demand and helps clients assess both market upside and commercialization risks.

4. U.S. In Vitro Diagnostics (IVD) Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. IVD Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Raw Materials and Diagnostic Components
4.4.2. Reagent and Assay Manufacturing
4.4.3. Instrument and Analyzer Manufacturing
4.4.4. Distribution and Logistics
4.4.5. Laboratory Testing and Clinical Utilization
4.5. Impact of Digitalization and Connected Laboratory Diagnostics
4.6. Application & Innovation Landscape
4.7. FDA IVD Regulatory Framework Analysis
4.7.1. 510(k) Premarket Notification Pathway
4.7.2. Premarket Approval Pathway
4.7.3. De Novo Classification Pathway
4.7.4. Emergency Use Authorization Considerations
4.7.5. Companion Diagnostic Regulatory Pathways
4.8. CLIA Regulatory and Laboratory Complexity Framework
4.8.1. CLIA-Waived Testing
4.8.2. Moderate-Complexity Testing
4.8.3. High-Complexity Testing
4.9. CMS Reimbursement and Coverage Landscape
4.9.1. Clinical Laboratory Fee Schedule
4.9.2. Advanced Diagnostic Laboratory Tests
4.9.3. Medicare Coverage Considerations
4.9.4. Commercial Payer Coverage Dynamics
4.10. Laboratory-Developed Test Regulatory Landscape
4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Initiatives and Public Health Diagnostic Programs
4.13. Impact of Escalating Geopolitical Tensions
4.14. Laboratory Value Analysis and Procurement Decision Framework
4.15. Laboratory Information Systems, Middleware and Interoperability Landscape

What this section provides: This section provides a complete view of the external IVD operating environment, including FDA regulation, CLIA, reimbursement, LDT policy, pricing, supply chains, laboratory automation, digitalization, interoperability, and purchasing dynamics.

5. U.S. In Vitro Diagnostics (IVD) Market – By Product & Service

5.1. Overview
5.1.1. Segment Share Analysis, By Product & Service, 2025 & 2035 (%)
5.1.2. Reagents & Consumables
5.1.2.1. Assay Reagents
5.1.2.2. Test Kits and Cartridges
5.1.2.3. Calibrators and Quality Controls
5.1.2.4. Molecular Diagnostic Consumables
5.1.2.5. Pathology and Histology Reagents
5.1.2.6. Sequencing and Sample Preparation Consumables
5.1.3. Instruments & Analyzers
5.1.3.1. Clinical Chemistry Analyzers
5.1.3.2. Immunoassay Analyzers
5.1.3.3. Molecular Diagnostic Systems
5.1.3.4. Hematology Analyzers
5.1.3.5. Coagulation Analyzers
5.1.3.6. Microbiology Systems
5.1.3.7. Pathology and Digital Imaging Systems
5.1.3.8. Point-of-Care Diagnostic Instruments
5.1.4. Software & Laboratory Informatics
5.1.4.1. Laboratory Middleware
5.1.4.2. Data Management and Connectivity Software
5.1.4.3. AI-Enabled Diagnostic Interpretation Software
5.1.4.4. Remote Instrument and Quality Management Platforms
5.1.5. Diagnostic & Specialty Testing Services
5.1.5.1. Molecular and Genetic Testing Services
5.1.5.2. Oncology and Genomic Profiling Services
5.1.5.3. Esoteric and Reference Laboratory Testing
5.1.5.4. Pathology and Specialized Diagnostic Services

What this section provides: This section identifies the IVD product and service categories generating the largest revenue pools and assesses the recurring reagent, instrument, software, and specialty testing opportunities expected to shape market growth through 2035.

6. U.S. In Vitro Diagnostics (IVD) Market – By Technology

6.1. Overview
6.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
6.1.2. Immunoassay & Immunochemistry
6.1.2.1. Enzyme Immunoassay
6.1.2.2. Chemiluminescence Immunoassay
6.1.2.3. Fluorescence Immunoassay
6.1.2.4. Rapid Immunoassays
6.1.3. Clinical Chemistry
6.1.3.1. Basic Metabolic and Comprehensive Metabolic Testing
6.1.3.2. Renal and Liver Function Testing
6.1.3.3. Lipid and Cardiometabolic Testing
6.1.3.4. Enzyme and Protein Analysis
6.1.4. Molecular Diagnostics
6.1.4.1. Polymerase Chain Reaction
6.1.4.2. Real-Time PCR
6.1.4.3. Digital PCR
6.1.4.4. Nucleic Acid Amplification Testing
6.1.4.5. Next-Generation Sequencing
6.1.4.6. Hybridization and Molecular Probe Technologies
6.1.5. Hematology & Coagulation
6.1.5.1. Complete Blood Count and Cell Analysis
6.1.5.2. Digital Cell Morphology
6.1.5.3. Hemostasis and Coagulation Testing
6.1.5.4. Thrombosis and Platelet Function Testing
6.1.6. Microbiology & Other Advanced Diagnostic Technologies
6.1.6.1. Culture-Based Diagnostics
6.1.6.2. Antimicrobial Susceptibility Testing
6.1.6.3. MALDI-TOF Mass Spectrometry
6.1.6.4. Flow Cytometry
6.1.6.5. Histology and Cytology
6.1.6.6. Immunohistochemistry
6.1.6.7. Urinalysis
6.1.6.8. Digital Pathology and AI-Assisted Diagnostics

What this section provides: This section evaluates the diagnostic technology platforms driving the U.S. IVD industry and identifies where molecular diagnostics, immunochemistry, automation, digital pathology, and other advanced technologies are gaining clinical and commercial value.

7. U.S. In Vitro Diagnostics (IVD) Market – By Application

7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
7.1.2. Infectious Disease Diagnostics
7.1.2.1. Respiratory Infections
7.1.2.2. Sexually Transmitted Infections
7.1.2.3. HIV and Viral Hepatitis
7.1.2.4. Gastrointestinal Infections
7.1.2.5. Urinary Tract Infections
7.1.2.6. Bloodstream Infections and Sepsis
7.1.2.7. Hospital-Acquired Infections
7.1.2.8. Antimicrobial Resistance Testing
7.1.3. Oncology Diagnostics
7.1.3.1. Tissue-Based Cancer Diagnostics
7.1.3.2. Immunohistochemistry
7.1.3.3. Companion Diagnostics
7.1.3.4. Comprehensive Genomic Profiling
7.1.3.5. Liquid Biopsy
7.1.3.6. Molecular Residual Disease Testing
7.1.4. Diabetes & Metabolic Disease Diagnostics
7.1.4.1. Glucose Testing
7.1.4.2. HbA1c Testing
7.1.4.3. Lipid and Cardiometabolic Testing
7.1.4.4. Diabetes-Related Renal Monitoring
7.1.5. Cardiology & Critical Care Diagnostics
7.1.5.1. Cardiac Biomarkers
7.1.5.2. Coagulation and Thrombosis Markers
7.1.5.3. Blood Gas and Electrolyte Testing
7.1.5.4. Sepsis and Inflammatory Biomarkers
7.1.6. Renal, Endocrine, Autoimmune, Women’s Health & Other Applications
7.1.6.1. Renal Disease Diagnostics
7.1.6.2. Thyroid and Endocrine Testing
7.1.6.3. Autoimmune Disease Diagnostics
7.1.6.4. Women’s Health and Reproductive Diagnostics
7.1.6.5. Fertility and Pregnancy Testing
7.1.6.6. Therapeutic Drug Monitoring
7.1.6.7. Transplantation Diagnostics

What this section provides: This section helps clients prioritize the clinical applications generating the strongest testing volumes and premium diagnostic opportunities, including infectious disease, oncology, metabolic disease, critical care, and specialized diagnostics.

8. U.S. In Vitro Diagnostics (IVD) Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Hospitals & Health Systems
8.1.2.1. Central Hospital Laboratories
8.1.2.2. Emergency and Critical Care Testing
8.1.2.3. Hospital Molecular Laboratories
8.1.2.4. Hospital Pathology Departments
8.1.2.5. Hospital Point-of-Care Networks
8.1.3. Independent & Reference Laboratories
8.1.3.1. National Reference Laboratories
8.1.3.2. Regional Laboratories
8.1.3.3. Specialty and Esoteric Laboratories
8.1.3.4. Molecular and Genetic Laboratories
8.1.4. Physician Offices, Clinics, Urgent-Care & Ambulatory Facilities
8.1.4.1. Physician Office Laboratories
8.1.4.2. Urgent-Care Centers
8.1.4.3. Ambulatory Care Facilities
8.1.4.4. Retail and Pharmacy-Based Testing
8.1.5. Academic, Specialty, Oncology & Research Laboratories
8.1.5.1. Academic Medical Center Laboratories
8.1.5.2. Oncology and Precision Medicine Laboratories
8.1.5.3. Clinical Research and Trial Laboratories
8.1.5.4. Public Health Laboratories
8.1.6. Home & Consumer Testing
8.1.6.1. At-Home Diagnostic Tests
8.1.6.2. Self-Collection Testing
8.1.6.3. Home Monitoring Diagnostics
8.1.6.4. Direct-to-Consumer Testing

What this section provides: This section explains which laboratory and care settings generate the largest IVD purchasing volumes and where decentralized, specialty, hospital, reference laboratory, and consumer testing demand is expanding.

9. U.S. In Vitro Diagnostics (IVD) Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Laboratory and Health System Procurement
9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.4. Group Purchasing Organization Contracts
9.1.5. Distributor and Laboratory Supply Channel Sales
9.1.6. Reference and Specialty Laboratory Contracting
9.1.7. Point-of-Care and Decentralized Testing Procurement

What this section provides: This section explains how IVD instruments, reagents, consumables, software, and diagnostic services are purchased in the United States and assesses the influence of direct contracting, IDNs, GPOs, distributors, and decentralized testing channels.

10. U.S. In Vitro Diagnostics (IVD) Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Laboratory Testing Volume and Infrastructure Analysis
10.1.4. Regional Chronic Disease and Diagnostic Demand Analysis
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional Molecular and Precision Diagnostics Adoption Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region IVD Key Manufacturers, Laboratories and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region IVD Key Manufacturers, Laboratories and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region IVD Key Manufacturers, Laboratories and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region IVD Key Manufacturers, Laboratories and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product & Service, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level intelligence across all 50 states, enabling clients to identify diagnostic testing hubs, laboratory infrastructure concentration, molecular diagnostics adoption hotspots, high-burden disease markets, procurement patterns, and state-level commercial opportunities.

11. U.S. In Vitro Diagnostics (IVD) Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking by Product Portfolio
11.3. Competitive Benchmarking by Technology Platform
11.4. Competitive Benchmarking by Clinical Application
11.5. Installed-Base and Reagent Pull-Through Positioning
11.6. Company Positioning Matrix
11.6.1. Leaders
11.6.2. Challengers
11.6.3. Innovators
11.6.4. Emerging Players
11.7. Merger, Acquisition and Strategic Partnership Landscape
11.8. Company Profiles

11.8.1. Roche Diagnostics
11.8.2. Abbott Laboratories
11.8.3. Siemens Healthineers
11.8.4. Beckman Coulter Diagnostics
11.8.5. Cepheid
11.8.6. Thermo Fisher Scientific
11.8.7. Becton, Dickinson and Company
11.8.8. bioMérieux
11.8.9. QuidelOrtho Corporation
11.8.10. Hologic
11.8.11. Sysmex Corporation
11.8.12. Bio-Rad Laboratories
11.8.13. QIAGEN
11.8.14. Agilent Technologies
11.8.15. Illumina
11.8.16. DiaSorin
11.8.17. Werfen
11.8.18. Revvity
11.8.19. Fujirebio
11.8.20. SEKISUI Diagnostics
11.8.21. Exact Sciences
11.8.22. Guardant Health
11.8.23. Natera
11.8.24. Caris Life Sciences
11.8.25. Labcorp

Note: Each company profile will include company overview, U.S. IVD portfolio, assay and instrument positioning, technology focus, installed-base strategy, reagent economics, U.S. commercialization strategy, financial positioning, regulatory approvals, pipeline developments, partnerships, acquisitions, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market share visibility, assay and instrument portfolio positioning, installed-base intelligence, innovation direction, and strategic profiles of major companies participating in the U.S. IVD ecosystem.

12. U.S. In Vitro Diagnostics (IVD) Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Liquid Biopsy and Molecular Residual Disease Testing
12.2.2. Next-Generation Sequencing and Companion Diagnostics
12.2.3. AI-Assisted Digital Pathology and Diagnostic Interpretation
12.2.4. Decentralized Molecular and Point-of-Care Testing
12.2.5. Total Laboratory Automation, Middleware and Intelligent Workflow
12.3. Future of Clinical Chemistry and Immunoassay Consolidation
12.4. Future of Molecular Infectious Disease Testing
12.5. Future of Precision Oncology Diagnostics
12.6. Emerging Business Trends
12.7. Recurring Reagent Revenue and Installed-Base Evolution
12.8. Business Opportunities for Startups and Existing Players
12.9. Investment Prioritization Matrix

What this section provides: This section prepares clients for future shifts in testing technology, laboratory architecture, precision medicine, automation, reimbursement, recurring reagent economics, and competitive structure through 2035.

13. U.S. In Vitro Diagnostics (IVD) Market: Strategic Recommendations

13.1. Recommendations for IVD Manufacturers
13.2. Recommendations for Reagent and Assay Developers
13.3. Recommendations for Hospitals and Health Systems
13.4. Recommendations for Independent and Reference Laboratories
13.5. Recommendations for Pharmaceutical and Companion Diagnostic Partners
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for Distributors and Channel Partners
13.8. Recommendations for New Entrants and Diagnostic Startups
13.9. U.S. Go-to-Market Strategy Considerations
13.10. Instrument Placement and Reagent Pull-Through Strategy
13.11. Product Positioning and Assay Menu Expansion Guidance
13.12. Molecular and Precision Diagnostics Commercialization Strategy
13.13. State and Regional Market Prioritization Strategy

What this section provides: This section translates U.S. IVD market intelligence into actionable recommendations for product development, assay portfolio expansion, instrument placement, commercialization, laboratory contracting, geographic prioritization, investment, and competitive differentiation.

14. U.S. In Vitro Diagnostics (IVD) Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Regulatory and Reimbursement Data Limitation
14.7. Company and Market Share Estimation Limitation

What this section provides: This section clarifies the report’s scope, analytical limitations, forecasting assumptions, regulatory and reimbursement considerations, third-party data use, and legal boundaries.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. In Vitro Diagnostics (IVD) Market: Market Definition and Scope
TABLE 3: U.S. In Vitro Diagnostics (IVD) Market: Research Methodology Framework
TABLE 4: U.S. In Vitro Diagnostics (IVD) Market: Key Assumptions
TABLE 5: U.S. In Vitro Diagnostics (IVD) Market: Market Ecosystem Overview
TABLE 6: U.S. In Vitro Diagnostics (IVD) Market: Stakeholder Analysis
TABLE 7: U.S. In Vitro Diagnostics (IVD) Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. In Vitro Diagnostics (IVD) Market: Analyst Viewpoint Summary
TABLE 9: U.S. In Vitro Diagnostics (IVD) Market: Market Attractiveness Index
TABLE 10: U.S. In Vitro Diagnostics (IVD) Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. In Vitro Diagnostics (IVD) Market: Base Year Market Positioning, 2025
TABLE 12: U.S. In Vitro Diagnostics (IVD) Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. In Vitro Diagnostics (IVD) Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. In Vitro Diagnostics (IVD) Market: High-Growth Opportunity Areas
TABLE 15: U.S. In Vitro Diagnostics (IVD) Market: Laboratory Testing Volume and Reagent Consumption Outlook
TABLE 16: U.S. In Vitro Diagnostics (IVD) Market: Drivers; Impact Analysis
TABLE 17: U.S. In Vitro Diagnostics (IVD) Market: Restraints; Impact Analysis
TABLE 18: U.S. In Vitro Diagnostics (IVD) Market: Opportunities; Impact Analysis
TABLE 19: U.S. In Vitro Diagnostics (IVD) Market: Challenges; Impact Analysis
TABLE 20: U.S. In Vitro Diagnostics (IVD) Market: Patent & Innovation Analysis, 2021–2025
TABLE 21: U.S. In Vitro Diagnostics (IVD) Market: Clinical Laboratory Workflow Economics Matrix
TABLE 22: U.S. In Vitro Diagnostics (IVD) Market: Reagent Pull-Through and Installed-Base Economics Matrix
TABLE 23: U.S. In Vitro Diagnostics (IVD) Market: Laboratory Automation and Staffing Productivity Matrix
TABLE 24: U.S. In Vitro Diagnostics (IVD) Market: Health System and Reference Laboratory Procurement Behavior Matrix
TABLE 25: U.S. In Vitro Diagnostics (IVD) Market: PESTEL Analysis
TABLE 26: U.S. In Vitro Diagnostics (IVD) Market: Porter’s Five Forces Analysis
TABLE 27: U.S. In Vitro Diagnostics (IVD) Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 28: U.S. In Vitro Diagnostics (IVD) Market: Value Chain Analysis
TABLE 29: U.S. In Vitro Diagnostics (IVD) Market: Supply Chain Analysis
TABLE 30: U.S. In Vitro Diagnostics (IVD) Market: Digitalization and Connected Laboratory Diagnostics Impact
TABLE 31: U.S. In Vitro Diagnostics (IVD) Market: Application & Innovation Landscape
TABLE 32: U.S. In Vitro Diagnostics (IVD) Market: FDA IVD Regulatory Framework Analysis
TABLE 33: U.S. In Vitro Diagnostics (IVD) Market: CLIA Regulatory and Laboratory Complexity Framework
TABLE 34: U.S. In Vitro Diagnostics (IVD) Market: CMS Reimbursement and Coverage Landscape
TABLE 35: U.S. In Vitro Diagnostics (IVD) Market: Laboratory-Developed Test Regulatory Landscape
TABLE 36: U.S. In Vitro Diagnostics (IVD) Market: Import/Export Restrictions & Tariff Impact
TABLE 37: U.S. In Vitro Diagnostics (IVD) Market: Government Initiatives and Public Health Diagnostic Programs
TABLE 38: U.S. In Vitro Diagnostics (IVD) Market: Impact of Escalating Geopolitical Tensions
TABLE 39: U.S. In Vitro Diagnostics (IVD) Market: Laboratory Value Analysis and Procurement Decision Framework
TABLE 40: U.S. In Vitro Diagnostics (IVD) Market: Laboratory Information Systems, Middleware and Interoperability Landscape
TABLE 41: U.S. In Vitro Diagnostics (IVD) Market: Product & Service Snapshot, 2025
TABLE 42: Segment Dashboard; Definition and Scope, by Product & Service
TABLE 43: U.S. In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 44: U.S. In Vitro Diagnostics (IVD) Market: Segment Share Analysis, by Product & Service, 2025 & 2035 (%)
TABLE 45: U.S. In Vitro Diagnostics (IVD) Market: Reagents & Consumables Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. In Vitro Diagnostics (IVD) Market: Instruments & Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. In Vitro Diagnostics (IVD) Market: Software & Laboratory Informatics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. In Vitro Diagnostics (IVD) Market: Diagnostic & Specialty Testing Services Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. In Vitro Diagnostics (IVD) Market: Technology Snapshot, 2025
TABLE 50: Segment Dashboard; Definition and Scope, by Technology
TABLE 51: U.S. In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 52: U.S. In Vitro Diagnostics (IVD) Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 53: U.S. In Vitro Diagnostics (IVD) Market: Immunoassay & Immunochemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. In Vitro Diagnostics (IVD) Market: Clinical Chemistry Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. In Vitro Diagnostics (IVD) Market: Molecular Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. In Vitro Diagnostics (IVD) Market: Hematology & Coagulation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. In Vitro Diagnostics (IVD) Market: Microbiology & Other Advanced Diagnostic Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. In Vitro Diagnostics (IVD) Market: Application Snapshot, 2025
TABLE 59: Segment Dashboard; Definition and Scope, by Application
TABLE 60: U.S. In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 61: U.S. In Vitro Diagnostics (IVD) Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 62: U.S. In Vitro Diagnostics (IVD) Market: Infectious Disease Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. In Vitro Diagnostics (IVD) Market: Oncology Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. In Vitro Diagnostics (IVD) Market: Diabetes & Metabolic Disease Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. In Vitro Diagnostics (IVD) Market: Cardiology & Critical Care Diagnostics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. In Vitro Diagnostics (IVD) Market: Renal, Endocrine, Autoimmune, Women’s Health & Other Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. In Vitro Diagnostics (IVD) Market: End User Snapshot, 2025
TABLE 68: Segment Dashboard; Definition and Scope, by End User
TABLE 69: U.S. In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 70: U.S. In Vitro Diagnostics (IVD) Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 71: U.S. In Vitro Diagnostics (IVD) Market: Hospitals & Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. In Vitro Diagnostics (IVD) Market: Independent & Reference Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. In Vitro Diagnostics (IVD) Market: Physician Offices, Clinics, Urgent-Care & Ambulatory Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. In Vitro Diagnostics (IVD) Market: Academic, Specialty, Oncology & Research Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. In Vitro Diagnostics (IVD) Market: Home & Consumer Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. In Vitro Diagnostics (IVD) Market: Procurement Channel Snapshot, 2025
TABLE 77: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 78: U.S. In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 79: U.S. In Vitro Diagnostics (IVD) Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 80: U.S. In Vitro Diagnostics (IVD) Market: Direct Laboratory and Health System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. In Vitro Diagnostics (IVD) Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. In Vitro Diagnostics (IVD) Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. In Vitro Diagnostics (IVD) Market: Distributor and Laboratory Supply Channel Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. In Vitro Diagnostics (IVD) Market: Reference and Specialty Laboratory Contracting Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. In Vitro Diagnostics (IVD) Market: Point-of-Care and Decentralized Testing Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. In Vitro Diagnostics (IVD) Market: Regional Snapshot, 2025
TABLE 87: Segment Dashboard; Definition and Scope, by Region
TABLE 88: U.S. In Vitro Diagnostics (IVD) Market, by Region, 2021–2035 (US$ Billion)
TABLE 89: U.S. In Vitro Diagnostics (IVD) Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 90: U.S. In Vitro Diagnostics (IVD) Market: Regional Laboratory Testing Volume and Infrastructure Analysis
TABLE 91: U.S. In Vitro Diagnostics (IVD) Market: Regional Chronic Disease and Diagnostic Demand Analysis
TABLE 92: U.S. In Vitro Diagnostics (IVD) Market: Regional Reimbursement and Procurement Dynamics
TABLE 93: U.S. In Vitro Diagnostics (IVD) Market: Regional Molecular and Precision Diagnostics Adoption Analysis
TABLE 94: West Region U.S. In Vitro Diagnostics (IVD) Market: Regional Overview and Trends
TABLE 95: West Region U.S. In Vitro Diagnostics (IVD) Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 96: West Region U.S. In Vitro Diagnostics (IVD) Market, by State, 2021–2035 (US$ Billion)
TABLE 97: West Region U.S. In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 98: West Region U.S. In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 99: West Region U.S. In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 100: West Region U.S. In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 101: West Region U.S. In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 102: California In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 103: California In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 104: California In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 105: California In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 106: California In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 107: Washington In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 108: Washington In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 109: Washington In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 110: Washington In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 111: Washington In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 112: Arizona In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 113: Arizona In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 114: Arizona In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 115: Arizona In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 116: Arizona In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 117: Colorado In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 118: Colorado In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 119: Colorado In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 120: Colorado In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 121: Colorado In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 122: Oregon In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 123: Oregon In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 124: Oregon In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 125: Oregon In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 126: Oregon In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 127: Utah In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 128: Utah In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 129: Utah In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 130: Utah In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 131: Utah In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 132: Nevada In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 133: Nevada In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 134: Nevada In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 135: Nevada In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 136: Nevada In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 137: New Mexico In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 138: New Mexico In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 139: New Mexico In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 140: New Mexico In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 141: New Mexico In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 142: Idaho In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 143: Idaho In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 144: Idaho In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 145: Idaho In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 146: Idaho In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 147: Montana In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 148: Montana In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 149: Montana In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 150: Montana In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 151: Montana In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 152: Wyoming In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 153: Wyoming In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 154: Wyoming In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 155: Wyoming In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 156: Wyoming In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 157: Alaska In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 158: Alaska In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 159: Alaska In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 160: Alaska In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 161: Alaska In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 162: Hawaii In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 163: Hawaii In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 164: Hawaii In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 165: Hawaii In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 166: Hawaii In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 167: Northeast Region U.S. In Vitro Diagnostics (IVD) Market: Regional Overview and Trends
TABLE 168: Northeast Region U.S. In Vitro Diagnostics (IVD) Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 169: Northeast Region U.S. In Vitro Diagnostics (IVD) Market, by State, 2021–2035 (US$ Billion)
TABLE 170: Northeast Region U.S. In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 171: Northeast Region U.S. In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 172: Northeast Region U.S. In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 173: Northeast Region U.S. In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 174: Northeast Region U.S. In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 175: New York In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 176: New York In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 177: New York In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 178: New York In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 179: New York In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 180: Massachusetts In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 181: Massachusetts In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 182: Massachusetts In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 183: Massachusetts In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 184: Massachusetts In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 185: New Jersey In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 186: New Jersey In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 187: New Jersey In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 188: New Jersey In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 189: New Jersey In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 190: Pennsylvania In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 191: Pennsylvania In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 192: Pennsylvania In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 193: Pennsylvania In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 194: Pennsylvania In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 195: Connecticut In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 196: Connecticut In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 197: Connecticut In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 198: Connecticut In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 199: Connecticut In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 200: Maine In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 201: Maine In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 202: Maine In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 203: Maine In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 204: Maine In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 205: Vermont In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 206: Vermont In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 207: Vermont In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 208: Vermont In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 209: Vermont In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 210: New Hampshire In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 211: New Hampshire In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 212: New Hampshire In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 213: New Hampshire In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 214: New Hampshire In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 215: Rhode Island In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 216: Rhode Island In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 217: Rhode Island In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 218: Rhode Island In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 219: Rhode Island In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 220: Delaware In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 221: Delaware In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 222: Delaware In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 223: Delaware In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 224: Delaware In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 225: South Region U.S. In Vitro Diagnostics (IVD) Market: Regional Overview and Trends
TABLE 226: South Region U.S. In Vitro Diagnostics (IVD) Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 227: South Region U.S. In Vitro Diagnostics (IVD) Market, by State, 2021–2035 (US$ Billion)
TABLE 228: South Region U.S. In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 229: South Region U.S. In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 230: South Region U.S. In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 231: South Region U.S. In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 232: South Region U.S. In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 233: Texas In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 234: Texas In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 235: Texas In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 236: Texas In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 237: Texas In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 238: Florida In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 239: Florida In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 240: Florida In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 241: Florida In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 242: Florida In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 243: Georgia In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 244: Georgia In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 245: Georgia In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 246: Georgia In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 247: Georgia In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 248: North Carolina In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 249: North Carolina In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 250: North Carolina In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 251: North Carolina In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 252: North Carolina In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 253: Tennessee In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 254: Tennessee In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 255: Tennessee In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 256: Tennessee In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 257: Tennessee In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 258: South Carolina In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 259: South Carolina In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 260: South Carolina In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 261: South Carolina In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 262: South Carolina In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 263: Alabama In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 264: Alabama In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 265: Alabama In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 266: Alabama In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 267: Alabama In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 268: Mississippi In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 269: Mississippi In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 270: Mississippi In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 271: Mississippi In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 272: Mississippi In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 273: Louisiana In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 274: Louisiana In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 275: Louisiana In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 276: Louisiana In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 277: Louisiana In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 278: Arkansas In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 279: Arkansas In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 280: Arkansas In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 281: Arkansas In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 282: Arkansas In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 283: Kentucky In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 284: Kentucky In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 285: Kentucky In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 286: Kentucky In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 287: Kentucky In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 288: Oklahoma In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 289: Oklahoma In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 290: Oklahoma In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 291: Oklahoma In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 292: Oklahoma In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 293: Virginia In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 294: Virginia In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 295: Virginia In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 296: Virginia In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 297: Virginia In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 298: Maryland In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 299: Maryland In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 300: Maryland In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 301: Maryland In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 302: Maryland In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 303: West Virginia In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 304: West Virginia In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 305: West Virginia In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 306: West Virginia In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 307: West Virginia In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 308: Midwest Region U.S. In Vitro Diagnostics (IVD) Market: Regional Overview and Trends
TABLE 309: Midwest Region U.S. In Vitro Diagnostics (IVD) Market: Key Manufacturers, Laboratories and Procurement Ecosystem
TABLE 310: Midwest Region U.S. In Vitro Diagnostics (IVD) Market, by State, 2021–2035 (US$ Billion)
TABLE 311: Midwest Region U.S. In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 312: Midwest Region U.S. In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 313: Midwest Region U.S. In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 314: Midwest Region U.S. In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 315: Midwest Region U.S. In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 316: Illinois In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 317: Illinois In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 318: Illinois In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 319: Illinois In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 320: Illinois In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 321: Ohio In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 322: Ohio In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 323: Ohio In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 324: Ohio In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 325: Ohio In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 326: Michigan In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 327: Michigan In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 328: Michigan In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 329: Michigan In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 330: Michigan In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 331: Minnesota In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 332: Minnesota In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 333: Minnesota In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 334: Minnesota In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 335: Minnesota In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 336: Indiana In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 337: Indiana In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 338: Indiana In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 339: Indiana In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 340: Indiana In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 341: Wisconsin In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 342: Wisconsin In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 343: Wisconsin In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 344: Wisconsin In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 345: Wisconsin In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 346: Missouri In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 347: Missouri In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 348: Missouri In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 349: Missouri In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 350: Missouri In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 351: Iowa In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 352: Iowa In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 353: Iowa In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 354: Iowa In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 355: Iowa In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 356: Kansas In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 357: Kansas In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 358: Kansas In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 359: Kansas In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 360: Kansas In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 361: Nebraska In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 362: Nebraska In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 363: Nebraska In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 364: Nebraska In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 365: Nebraska In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 366: North Dakota In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 367: North Dakota In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 368: North Dakota In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 369: North Dakota In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 370: North Dakota In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 371: South Dakota In Vitro Diagnostics (IVD) Market, by Product & Service, 2021–2035 (US$ Billion)
TABLE 372: South Dakota In Vitro Diagnostics (IVD) Market, by Technology, 2021–2035 (US$ Billion)
TABLE 373: South Dakota In Vitro Diagnostics (IVD) Market, by Application, 2021–2035 (US$ Billion)
TABLE 374: South Dakota In Vitro Diagnostics (IVD) Market, by End User, 2021–2035 (US$ Billion)
TABLE 375: South Dakota In Vitro Diagnostics (IVD) Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 376: U.S. In Vitro Diagnostics (IVD) Market: Competitive Landscape Snapshot, 2025
TABLE 377: U.S. In Vitro Diagnostics (IVD) Market: Key Company Market Share Analysis, 2025
TABLE 378: U.S. In Vitro Diagnostics (IVD) Market: Competitive Benchmarking by Product Portfolio
TABLE 379: U.S. In Vitro Diagnostics (IVD) Market: Competitive Benchmarking by Technology Platform
TABLE 380: U.S. In Vitro Diagnostics (IVD) Market: Competitive Benchmarking by Clinical Application
TABLE 381: U.S. In Vitro Diagnostics (IVD) Market: Installed-Base and Reagent Pull-Through Positioning
TABLE 382: U.S. In Vitro Diagnostics (IVD) Market: Company Positioning Matrix
TABLE 383: U.S. In Vitro Diagnostics (IVD) Market: M&A, Partnerships and Strategic Developments
TABLE 384: Roche Diagnostics: Company Profile
TABLE 385: Abbott Laboratories: Company Profile
TABLE 386: Siemens Healthineers: Company Profile
TABLE 387: Beckman Coulter Diagnostics: Company Profile
TABLE 388: Cepheid: Company Profile
TABLE 389: Thermo Fisher Scientific: Company Profile
TABLE 390: Becton, Dickinson and Company: Company Profile
TABLE 391: bioMérieux: Company Profile
TABLE 392: QuidelOrtho Corporation: Company Profile
TABLE 393: Hologic: Company Profile
TABLE 394: Sysmex Corporation: Company Profile
TABLE 395: Bio-Rad Laboratories: Company Profile
TABLE 396: QIAGEN: Company Profile
TABLE 397: Agilent Technologies: Company Profile
TABLE 398: Illumina: Company Profile
TABLE 399: DiaSorin: Company Profile
TABLE 400: Werfen: Company Profile
TABLE 401: Revvity: Company Profile
TABLE 402: Fujirebio: Company Profile
TABLE 403: SEKISUI Diagnostics: Company Profile
TABLE 404: Exact Sciences: Company Profile
TABLE 405: Guardant Health: Company Profile
TABLE 406: Natera: Company Profile
TABLE 407: Caris Life Sciences: Company Profile
TABLE 408: Labcorp: Company Profile
TABLE 409: U.S. In Vitro Diagnostics (IVD) Market: Future Market Scenario Analysis, 2026–2035
TABLE 410: U.S. In Vitro Diagnostics (IVD) Market: Disruptive Technologies Impact Matrix
TABLE 411: U.S. In Vitro Diagnostics (IVD) Market: Future of Clinical Chemistry and Immunoassay Consolidation
TABLE 412: U.S. In Vitro Diagnostics (IVD) Market: Future of Molecular Infectious Disease Testing
TABLE 413: U.S. In Vitro Diagnostics (IVD) Market: Future of Precision Oncology Diagnostics
TABLE 414: U.S. In Vitro Diagnostics (IVD) Market: Emerging Business Trends
TABLE 415: U.S. In Vitro Diagnostics (IVD) Market: Recurring Reagent Revenue and Installed-Base Evolution
TABLE 416: U.S. In Vitro Diagnostics (IVD) Market: Business Opportunities for Startups and Existing Players
TABLE 417: U.S. In Vitro Diagnostics (IVD) Market: Investment Prioritization Matrix
TABLE 418: U.S. In Vitro Diagnostics (IVD) Market: Strategic Recommendations for IVD Manufacturers
TABLE 419: U.S. In Vitro Diagnostics (IVD) Market: Strategic Recommendations for Reagent and Assay Developers
TABLE 420: U.S. In Vitro Diagnostics (IVD) Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 421: U.S. In Vitro Diagnostics (IVD) Market: Strategic Recommendations for Independent and Reference Laboratories
TABLE 422: U.S. In Vitro Diagnostics (IVD) Market: Strategic Recommendations for Pharmaceutical and Companion Diagnostic Partners
TABLE 423: U.S. In Vitro Diagnostics (IVD) Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 424: U.S. In Vitro Diagnostics (IVD) Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 425: U.S. In Vitro Diagnostics (IVD) Market: Strategic Recommendations for New Entrants and Diagnostic Startups
TABLE 426: U.S. In Vitro Diagnostics (IVD) Market: U.S. Go-to-Market Strategy Considerations
TABLE 427: U.S. In Vitro Diagnostics (IVD) Market: Instrument Placement and Reagent Pull-Through Strategy
TABLE 428: U.S. In Vitro Diagnostics (IVD) Market: Product Positioning and Assay Menu Expansion Guidance
TABLE 429: U.S. In Vitro Diagnostics (IVD) Market: Molecular and Precision Diagnostics Commercialization Strategy
TABLE 430: U.S. In Vitro Diagnostics (IVD) Market: State and Regional Market Prioritization Strategy
TABLE 431: U.S. In Vitro Diagnostics (IVD) Market: Scope Limitation
TABLE 432: U.S. In Vitro Diagnostics (IVD) Market: Data Use Limitation
TABLE 433: U.S. In Vitro Diagnostics (IVD) Market: Forecasting Limitation
TABLE 434: U.S. In Vitro Diagnostics (IVD) Market: Legal Disclaimer
TABLE 435: U.S. In Vitro Diagnostics (IVD) Market: Third-Party Data Disclaimer
TABLE 436: U.S. In Vitro Diagnostics (IVD) Market: Regulatory and Reimbursement Data Limitation
TABLE 437: U.S. In Vitro Diagnostics (IVD) Market: Company and Market Share Estimation Limitation

List of Figures

FIGURE 1: U.S. In Vitro Diagnostics (IVD) Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Laboratory Workflow Economics Framework
FIGURE 11: Reagent Pull-Through and Installed-Base Economics Framework
FIGURE 12: Laboratory Automation and Staffing Productivity Framework
FIGURE 13: Laboratory Procurement Decision Framework
FIGURE 14: U.S. In Vitro Diagnostics (IVD) Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 15: U.S. In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 16: U.S. In Vitro Diagnostics (IVD) Market Year-wise Growth Curve, 2021–2035
FIGURE 17: Product & Service Segment Market Share Analysis, 2025 & 2035
FIGURE 18: Product & Service Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Reagents & Consumables Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Instruments & Analyzers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Software & Laboratory Informatics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Diagnostic & Specialty Testing Services Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 24: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Immunoassay & Immunochemistry Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Clinical Chemistry Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Molecular Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Hematology & Coagulation Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Microbiology & Other Advanced Diagnostic Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 31: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Infectious Disease Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Oncology Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Diabetes & Metabolic Disease Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Cardiology & Critical Care Diagnostics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Renal, Endocrine, Autoimmune, Women’s Health & Other Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 38: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Hospitals & Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Independent & Reference Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Physician Offices, Clinics, Urgent-Care & Ambulatory Facilities Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Academic, Specialty, Oncology & Research Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Home & Consumer Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 45: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Direct Laboratory and Health System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Distributor and Laboratory Supply Channel Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Reference and Specialty Laboratory Contracting Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Point-of-Care and Decentralized Testing Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 53: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: West Region U.S. In Vitro Diagnostics (IVD) Market Share and Leading Players, 2025
FIGURE 55: West Region Market Share Analysis by State, 2025
FIGURE 56: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: California In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Washington In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Arizona In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Colorado In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Oregon In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Utah In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Nevada In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: New Mexico In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Idaho In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Montana In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Wyoming In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Alaska In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Hawaii In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Northeast Region U.S. In Vitro Diagnostics (IVD) Market Share and Leading Players, 2025
FIGURE 71: Northeast Region Market Share Analysis by State, 2025
FIGURE 72: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New York In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Massachusetts In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: New Jersey In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Pennsylvania In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Connecticut In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Maine In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Vermont In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New Hampshire In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Rhode Island In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Delaware In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: South Region U.S. In Vitro Diagnostics (IVD) Market Share and Leading Players, 2025
FIGURE 84: South Region Market Share Analysis by State, 2025
FIGURE 85: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Texas In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Florida In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Georgia In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: North Carolina In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Tennessee In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: South Carolina In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Alabama In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Mississippi In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Louisiana In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Arkansas In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Kentucky In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Oklahoma In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Virginia In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Maryland In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: West Virginia In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Midwest Region U.S. In Vitro Diagnostics (IVD) Market Share and Leading Players, 2025
FIGURE 102: Midwest Region Market Share Analysis by State, 2025
FIGURE 103: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Illinois In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Ohio In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Michigan In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Minnesota In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Indiana In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Wisconsin In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Missouri In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Iowa In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Kansas In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Nebraska In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: North Dakota In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: South Dakota In Vitro Diagnostics (IVD) Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 117: Company Positioning Matrix
FIGURE 118: Key Player Product Portfolio Benchmarking
FIGURE 119: Technology Platform Competitive Benchmarking
FIGURE 120: Clinical Application Competitive Benchmarking
FIGURE 121: Installed-Base and Reagent Pull-Through Competitive Positioning
FIGURE 122: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 123: U.S. IVD Innovation Roadmap
FIGURE 124: Liquid Biopsy and Molecular Residual Disease Opportunity Map
FIGURE 125: Next-Generation Sequencing and Companion Diagnostics Roadmap
FIGURE 126: AI-Assisted Digital Pathology Adoption Roadmap
FIGURE 127: Decentralized Molecular and Point-of-Care Diagnostics Growth Roadmap
FIGURE 128: Laboratory Automation and Middleware Evolution Roadmap
FIGURE 129: Future Market Scenario Analysis, 2026–2035
FIGURE 130: Disruptive Technologies Impact Matrix
FIGURE 131: Emerging Business Trends Matrix
FIGURE 132: Recurring Reagent Revenue and Installed-Base Evolution
FIGURE 133: Investment Prioritization Matrix
FIGURE 134: Strategic Growth Roadmap for U.S. IVD Companies
FIGURE 135: U.S. Go-to-Market Strategy Framework
FIGURE 136: Instrument Placement and Reagent Pull-Through Strategy Framework
FIGURE 137: Product Positioning and Assay Menu Expansion Framework
FIGURE 138: Molecular and Precision Diagnostics Commercialization Framework
FIGURE 139: State and Regional Market Prioritization Framework
FIGURE 140: Report Scope and Disclaimer Framework